Hurdles in therapy with regulatory T cells
2015 (English)In: Science Translational Medicine, ISSN 1946-6234, E-ISSN 1946-6242, Vol. 7, no 304, 304ps18Article in journal (Refereed) Published
Improper activation of the immune system contributes to a variety of clinical conditions, including autoimmune and allergic diseases as well as solid organ and bone marrow transplantation. One approach to counteract this activation is through adoptive therapy with regulatory T cells (T-regs). Efforts to manufacture these cells have led to good maunfacturing practice-compliant protocols, and T-reg products are entering early clinical trials. Here, we report the stance of the European Union Cooperation in Science and Technology Action BM1305, "Action to Focus and Accelerate Cell-based Tolerance-inducing Therapies-A FACTT," which identifies hurdles hindering T-reg clinical applications in Europe and provides possible solutions.
Place, publisher, year, edition, pages
2015. Vol. 7, no 304, 304ps18
IdentifiersURN: urn:nbn:se:uu:diva-264052DOI: 10.1126/scitranslmed.aaa7721ISI: 000360943900002OAI: oai:DiVA.org:uu-264052DiVA: diva2:859031
FunderEU, FP7, Seventh Framework Programme